PARP inhibitor "Lynparza (Olaparib)" has expanded its indications to pancreatic and prostate cancer. AstraZeneca Korea announced on the 7th that it has been approved by the MFDS for Lynparza's indications for pancreatic and prostate cancer.

As a result, Lynparza can be used for ▲ maintenance therapy in adult patients with gBRCA mutated pancreatic cancer who have not undergone chemotherapy for at least 16 weeks after receiving 1st platinum-based chemotherapy and ▲ for treating adult patients with BRCA mutated metastatic castration-resistant prostate cancer who have previously progressed after treatment of new hormone treatments.

The approval for pancreatic cancer and prostate cancer indi